Last reviewed · How we verify
ASTX030
At a glance
| Generic name | ASTX030 |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (PHASE2, PHASE3)
- A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASTX030 CI brief — competitive landscape report
- ASTX030 updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI